The Gates Foundation Trust has completely divested from Microsoft after decades of slowly selling its position. The $31.6 billion endowment has instead added West Pharmaceutical Services (WST) to its portfolio, a healthcare stock with 32 consecutive years of dividend increases and forecasted earnings growth of 14-15% annually through 2027, positioning it as a potential future Dividend King.

President Trump purchased up to $680,000 in Eli Lilly shares and $250,000-$500,000 in West Pharmaceutical shares in early 2026, with purchases coinciding with new Medicare policies favoring GLP-1 obesity drugs. Eli Lilly was selected for a CMS pilot program offering GLP-1 drugs at $50/month. The Trump Organization stated investments are independently managed through discretionary accounts.

West Pharmaceutical Services disclosed a material cyberattack on May 7 where unauthorized parties exfiltrated data and encrypted systems. The company has restored core enterprise systems and resumed some operations, but the full scope of damage and financial impact remain unknown. William Blair maintains an Outperform rating despite near-term uncertainty, citing the company's strong market position. WST shares fell 2.02% on the news.

The global medical device contract development and manufacturing organization (CDMO) market is expected to expand significantly at a CAGR of 13.12% from 2026 to 2033, driven by increased outsourcing by OEMs, demand for advanced connected devices, and the shift toward home care and minimally invasive treatments. CDMOs are becoming essential partners for managing regulatory complexities, reducing capital expenditure, and accelerating time-to-market.

West Pharmaceutical reported strong Q1 2026 results with adjusted EPS of $2.13 (beating consensus of $1.68) and net sales of $844.90 million, up 21% year-over-year. The company raised its full-year 2026 guidance for both revenue and EPS, driven by robust demand for GLP-1 injectable components which contributed 10% of total sales. The board also authorized a new $1 billion share repurchase program.

The global pharmaceutical packaging market is projected to grow from USD 154.78 billion in 2025 to USD 219.08 billion by 2031, with a CAGR of 5.94%. Growth is driven by increasing demand for injectable therapies, sustainable packaging solutions, and stricter regulatory traceability requirements. Key trends include the shift toward recyclable materials, adoption of prefilled syringes, and advanced barrier systems.

Iron Mountain, US Foods, and West Pharmaceutical Services reported strong Q4 2025 earnings. Iron Mountain posted record results with 16.6% revenue growth driven by data center and digital services, projecting 10-13% revenue growth for 2026. US Foods achieved 178.8% net income growth despite softer economic conditions, while West Pharmaceutical delivered 7.5% revenue growth with strong performance in high-value product components.

Ten large-cap stocks experienced significant declines during the week of January 19-23, 2026. AeroVironment led losses with a 19.45% drop following a government stop work order. DraftKings fell 14.4% due to Massachusetts blocking sports-related contracts, while Abbott declined 12.23% after missing earnings expectations. Other major losers included AppLovin (14.68%), Shopify (13.51%), Flutter Entertainment (13.07%), and West Pharmaceutical Services (13.27%).

AbbVie announced a voluntary agreement with the Trump administration to lower drug prices for Medicaid while pledging $100 billion in U.S.-based R&D and capital investments over the next decade. In exchange, the company receives tariff exemptions and protection from future pricing mandates. AbbVie also announced a $650 million licensing deal with RemeGen for cancer drug RC148 and agreed to acquire a West Pharmaceutical Services manufacturing facility in Arizona for $175 million.

The global cell therapy packaging market is projected to grow from $404 million in 2025 to $1.22 billion by 2035, driven by personalized cell therapies and technological innovations in packaging solutions.

The global cell therapy packaging market is projected to grow from $419.57 million in 2025 to $1.27 billion by 2034, driven by increasing demand for cell and gene therapies, technological advancements, and specialized packaging solutions.

The global medical flexible packaging market is projected to grow from USD 21.48 billion in 2025 to USD 34.78 billion by 2034, with a 5.5% CAGR. Key growth drivers include rising pharmaceutical needs, sustainability focus, and increasing chronic disease prevalence.